STOCK TITAN

Clarivate Plc - $CLVT STOCK NEWS

Welcome to our dedicated page for Clarivate Plc news (Ticker: $CLVT), a resource for investors and traders seeking the latest updates and insights on Clarivate Plc stock.

Clarivate Plc (NYSE: CLVT) is a leading global provider of transformative intelligence, offering enriched data, insights, analytics, workflow solutions, and expert services across various sectors including Academia & Government, Intellectual Property, and Life Sciences & Healthcare. Formerly part of Thomson Reuters, Clarivate became an independent company in 2016 and went public on the New York Stock Exchange in 2019. The company is headquartered in London with operations in over 100 countries and a workforce of over 4,000 employees.

Clarivate serves a diverse clientele, ranging from academia, government, law, life sciences, and healthcare. Some of its most trusted brands include Web of Science™, Cortellis™, Derwent™, CompuMark™, MarkMonitor®, and Techstreet™. These brands offer specialized services such as scientific and academic research, patent analytics, pharmaceutical and biotech intelligence, and IP management. Researchers and organizations globally rely on Clarivate's curated knowledge bases to accelerate innovation and bring new ideas to market more efficiently.

Recently, Clarivate has been recognized for its ongoing efforts and achievements. The company has made significant strides in the realm of cancer treatment research, particularly in the area of CAR T-cell therapies. According to a three-part report published by BioWorld™, Clarivate is exploring the rapid pipeline growth and clinical trials in CAR T therapy development in China. This report is part of the company’s commitment to providing valuable insights into groundbreaking treatments and their potential market impacts.

Additionally, Clarivate has launched key updates to its Cortellis CMC Intelligence™ solution, introducing a new post-approval variations module. This update assists pharmaceutical, biotech, and generics companies in streamlining regulatory tracking and optimizing lifecycle management for both small molecules and biologics.

The company also introduced Epidemiology Intelligence™, combining epidemiological data with U.S. claims-based population insights to help biopharma companies accurately gauge market size and target patient demographics. Another significant launch was the Trademark Watch Analyzer, an AI-enhanced trademark protection solution providing faster and more accurate answers to critical business questions by leveraging global trademark and case law data.

Financially, Clarivate reported a slight decrease in revenues for the first quarter of 2024, yet showed resilience and strategic focus on long-term growth. The company continues to invest in product development and operational initiatives to drive future organic revenue growth. Their financial stability is underscored by substantial cash flow and a clear strategy for debt management.

Clarivate’s strategic partnerships, such as the recent collaboration with HealthWise Data, further enhance its offerings by integrating Social Determinants of Health (SDoH) attributes into its Real-World Data repository, contributing to enhanced patient outcomes and healthcare equity.

For more information about Clarivate, its products, and services, visit www.clarivate.com.

Rhea-AI Summary

Clarivate (NYSE: CLVT) has launched Research Horizon Navigator, an AI-native module within InCites Benchmarking & Analytics, designed to identify emerging research topics and future breakthrough areas. Utilizing data from the Web of Science Core Collection and a novel methodology by the Institute for Scientific Information, the tool highlights new research trends and provides insights for strategic investments. Research Horizon Navigator, available to InCites subscribers, offers interactive visualizations and identifies key contributors. Applications include technology watch, collaboration, funding program management, and research assessment, with continuous enhancements based on community feedback.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.8%
Tags
none
-
Rhea-AI Summary

Clarivate has partnered with HealthWise Data to integrate Social Determinants of Health (SDoH) attributes into its Real-World Data (RWD) repository. This collaboration aims to enhance patient insights and address healthcare equity by incorporating factors like income, education, and ethnicity. The integration will provide healthcare professionals with comprehensive data to improve patient outcomes and public health interventions.

Bob Morrison, VP of RWD Data Strategy and Operations at Clarivate, emphasizes the milestone's significance in delivering transformative insights. Anne Smith, CEO of HealthWise Data, highlights the improved patient view and outcomes resulting from the partnership. The enhanced RWD is expected to aid in identifying at-risk populations and facilitating targeted early prevention measures.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.42%
Tags
none
-
Rhea-AI Summary

Clarivate announced the automatic conversion of its 5.25% Series A Mandatory Convertible Preferred Shares into ordinary shares on June 3, 2024. Shareholders will receive 3.8462 ordinary shares per Preferred Share, with cash paid for fractional shares. A final quarterly cash dividend of $1.3125 per Preferred Share will be distributed to holders of record as of May 15, 2024. This move aligns with Clarivate's strategy to simplify its capital structure.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.42%
Tags
none
Rhea-AI Summary

Clarivate announces that 500 institutions, including Florida Atlantic University, have adopted its Rialto™ books marketplace solution. This highlights Rialto's rapid success in enhancing library collection management globally. The platform integrates with Alma, enabling real-time budget tracking and efficient resource ordering. Rialto offers features like AI-driven recommendations, a comprehensive marketplace, and seamless workflows to improve library operations.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.18%
Tags
none
-
Rhea-AI Summary

Clarivate Plc (NYSE: CLVT), a global provider of transformative intelligence, announced its participation in two investor conferences in June 2024.

CEO Jonathan Gear will present at the William Blair Growth Stock Conference on June 4 at 2:00 p.m. Central Time (3:00 p.m. Eastern Time), accessible via live webcast.

CFO Jonathan Collins will present at the Stifel Cross Sector Insight Conference on June 5 at 3:35 p.m. Eastern Time, also accessible via live webcast.

Replays of both webcasts will be available on Clarivate's investor relations website for 90 days.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.74%
Tags
conferences
-
Rhea-AI Summary

On May 22, 2024, Clarivate released its 'Medical Technologies to Watch in 2024' report, spotlighting five breakthrough medical technologies projected to generate significant clinical and commercial impact. These technologies include pulsed field ablation devices for atrial fibrillation, advanced diabetes care devices, neurostimulation devices, surgical robotics, and renal denervation technology for hypertension management. The report forecasts these technologies will generate over $1 billion in market value or achieve double-digit growth within the next five years. Challenges such as shifting service sites, global supply chain issues, and evolving policy landscapes are also acknowledged.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.33%
Tags
none
Rhea-AI Summary

Clarivate has released its Trademark Filing and Litigation Trends 2024 Report, highlighting a return to stability and growth in trademark filing activity globally. The report analyzes trademark registers from the U.S., EU, U.K., Mainland China, Japan, and South Korea, revealing that 2023 exhibited stable trademark filing activities surpassing pre-COVID levels, especially in the U.S., EU, and South Korea. The U.K. demonstrated sustained high growth, while Japan and Mainland China showed slower growth. Key sectors driving trademark applications include retail and business services, technology, and technical services. Mainland China and U.S. applicants led in filing applications across multiple regions, with L'Oreal emerging as a leading filer in several registers.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.52%
Tags
none
-
Rhea-AI Summary

Clarivate has launched the Trademark Watch Analyzer, an AI-enhanced solution aimed at improving trademark protection. Announced at the 2024 International Trademark Association Annual Meeting, this tool integrates global trademark and case law data, in-house IP expertise, and advanced AI technology. The analyzer covers trademark datasets from 258 countries and 191 trademark registers, along with data from over 7 million trademark litigation cases. This system automates key trademark watching tasks and prioritizes result sets, allowing clients to rank results based on success or opposition chances. According to CompuMark data, trademark applications have doubled since 2014, increasing the need for vigilant trademark monitoring. Gordon Samson, Clarivate's President of Intellectual Property, emphasized that this solution helps clients save time, cost, and resources while ensuring global trademark monitoring and automated alerts.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.33%
Tags
AI
-
Rhea-AI Summary

Clarivate released the 2024 Non-Practicing Entity (NPE) Global Litigation Report, detailing NPE enforcement activities and patent challenges globally. The U.S., Germany, and Mainland China lead in NPE litigation cases, with the U.S. accounting for 97.2% from 2018-2023, Germany 1.8%, and China 0.4%. The report notes a 43% decrease in U.S. NPE cases, a 600% increase in China, and a decline in Germany from 2018. The report found that overall NPE infringement actions declined globally from 2012-2019 and stabilized at around 2,000 cases per year starting in 2020. It also highlights that NPEs face higher patent invalidation rates compared to non-NPEs, indicating potential patent quality issues.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.29%
Tags
none
News
Rhea-AI Summary

OMRON, a leading automation company, has selected IPfolio™, an intellectual property management software from Clarivate Plc (NYSE: CLVT), to transform their IP operations. The solution aims to maximize operational efficiency by leveraging IP data and analytical insights, enabling OMRON to make smarter decisions and plan strategically. With IPfolio, OMRON can better manage its IP assets, increase productivity, and streamline processes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.3%
Tags
none

FAQ

What does Clarivate do?

Clarivate provides transformative intelligence, offering enriched data, insights, and analytics across sectors like Academia & Government, Intellectual Property, and Life Sciences & Healthcare.

What are some of Clarivate’s trusted brands?

Some of Clarivate’s most trusted brands include Web of Science™, Cortellis™, Derwent™, CompuMark™, MarkMonitor®, and Techstreet™.

Where is Clarivate headquartered?

Clarivate is headquartered in London and operates in over 100 countries.

How did Clarivate become an independent company?

Clarivate was formerly part of Thomson Reuters and became an independent company in 2016 after being sold to private equity.

When did Clarivate go public?

Clarivate went public on the New York Stock Exchange in 2019.

What recent advancements has Clarivate made in the field of cancer treatment?

Clarivate has been exploring the rapid pipeline growth and clinical trials in CAR T-cell therapies, particularly in China, as part of their commitment to innovative cancer treatments.

What is Cortellis CMC Intelligence™?

Cortellis CMC Intelligence™ is a solution that helps pharmaceutical, biotech, and generics companies streamline regulatory tracking and optimize lifecycle management for small molecules and biologics.

What is Epidemiology Intelligence™?

Epidemiology Intelligence™ combines epidemiological data with U.S. claims-based population insights to help biopharma companies accurately gauge market size and target patient demographics.

What is the purpose of the Trademark Watch Analyzer?

The Trademark Watch Analyzer is an AI-enhanced trademark protection solution that provides faster and more accurate answers to critical business questions by leveraging global trademark and case law data.

How does Clarivate enhance patient outcomes with HealthWise Data?

Clarivate's partnership with HealthWise Data integrates Social Determinants of Health (SDoH) attributes into its Real-World Data repository, offering nuanced patient insights to enhance outcomes and healthcare equity.

Clarivate Plc

NYSE:CLVT

CLVT Rankings

CLVT Stock Data

3.62B
404.04M
16.65%
92.2%
5.52%
Data Processing, Hosting, and Related Services
Information
Link
United States of America
ST. HELIER